How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1024-1033

  Broxterman, H J ^a   Lankelma, J ^a   Pinedo, H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCEIN; DAUNORUBICIN; GENE PRODUCT; GLYCOPROTEIN P; RIBONUCLEASE;

CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GOOD LABORATORY PRACTICE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; ISOTOPE LABELING; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOLID TUMOR;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOTTING, WESTERN; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; RNA, MESSENGER; RNA, NEOPLASM;

EID: 0029999404     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00045-7     Document Type: Article

References (86)

1. Fojo A, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistant gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84, 265-269.
2. Van der Valk P, Van Kalken CK, Ketelaars H, et al. Distribution of multidrug-resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990, 1, 56-64.
3. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87, 7160-7164.
4. Nooter K, Westerman A, Flens MJ, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995, 1, 1301-1310.
5. Zaman GJR, Versantvoort CHM, Smit JJM, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug-resistant lung cancer cell lines. Cancer Res 1993, 53, 1747-1750.
6. Broxterman HJ, Giaccone G, Lankelma J. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol 1995, 7, 532-540.
7. Flens MJ, Zaman GJR, Van der Valk P, et al. Tissue distribution of the multidrug resistance-associated protein (MRP). Am J Pathol, in press.
8. Cole SPC, Deeley RG. Multidrug resistance associated with overexpression of MRP. In Hait WN, ed. Adv Cancer Res, in press.
9. Haber DA. Multidrug resistance (MDR1) in leukemia: is it time to test? Blood 1992, 79, 295-298.
10. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81, 2215-2222.
11. Hedley DW. Flow cytometric assays of anticancer drug resistance. Clinical Flow Cytometry Series: Ann NY Acad Sci 1993, 677, 341-353.
12. Van Kalken CK, Van der Valk P, Hadisaputro MMN, et al. Differentiation dependent expression of P-glycoprotein in the normal and neoplastic human kidney. Ann Oncol 1991, 2, 55-62.
13. Bates SE, Regis JI, Robey RW, Zhan Z, Scala S, Meadows BJ. Chemo-resistance in the clinic: overview 1994. Bull Cancer 1994, 9 (Suppl.2), 55s-61s.
14. Holzmayer TA, Hilsenbeck S, von Hoff DD, Roninson IB. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992, 84, 1486-1491.
15. Zinn K, Dimaio D, Maniatis T. Identification of two distinct regulatory regions adjacent to the human β-interferon gene. Cell 1983, 34, 865-879.
16. Hengen PN. Quantitative PCR: an accurate measure of mRNA? Trends Biochem Sci 1995, 20, 476-477.
17. Kang YK, Zhan Z, Regis J, et al. Expression of mdr1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995, 86, 1515-1524.
18. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80, 2735-2739.
19. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992, 80, 2729-2734.
20. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83, 2451-2458.
21. Baas F, Jongsma APM, Broxterman HJ, et al. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res 1990, 50, 5392-5398.
22. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995, 1, 81-93.
23. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994, 54, 4676-4679.
24. Thomas GA, Barrand MA, Stewart S, Rabbitts PH, Williams ED, Twentyman PR. Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation. Eur J Cancer 1994, 30A, 1705-1709.
25. Herzog CE, Trepel JB, Mickley LA, Bates SE, Fojo AT. Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 1992, 84, 711-716.
26. Brophy NA, Marie JP, Rojas VA, et al. Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: a critical evaluation by four techniques. Leukemia 1994, 8, 327-335.
27. Van Kapel J, Nooter K, Oostrum RG, Sonneveld P. Western immunoblotting enhanced chemiluminescence (ECL) detection of P-glycoprotein in vinca-alkaloid resistant cell-lines and human leukemic cells. In Kaspers GJL, Pieters R, Twentyman PR, Weisenthal LM, Veerman AJP, eds. Drug Resistance in Leukemia and Lymphoma. Chur, Switzerland, Harwood Academic, 1993, 77-87.
28. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991, 51, 2628-2635.
29. Flens MJ, Izquierdo MA, Scheffer GL, et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res 1994, 54, 4557-4563.
30. Grogan T, Dalton W, Rybski J, et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 1990, 63, 815-824.
31. Broxterman HJ, Schuurhuis GJ, Lankelma J, Baak JPA, Pinedo HM. Towards functional screening for multidrug resistant cells in human malignancies. In Mihich E, ed. Pezcoller Foundation Symposium, Vol 1. Drug Resistance: Mechanisms and Reversal. Rome, John Libbey CIC, 1990, 309-319.
32. Chan HSL, DeBoer G, Haddad G, Gallie BL, Ling V. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin N Am 1995, 9, 275-318.
33. Kandel RA, Campbell S, Noble-Topham S, Bell R, Andrulis IL. Correlation of P-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas. Diagnostic Molec Pathol 1995, 4, 59-65.
34. Tóth K, Vaughan MM, Slocum HK, et al New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, parraffin-embedded human tissues. Am J Pathol 1994, 144, 227-236.
35. Beck WT, Grogan TM, Willman CL, et al. The St Jude workshop on methods to detect P-glycoprotein-associated multidrug resistance: findings and consensus recommendations. Cancer Res, in press.
36. Weinstein RS, Jakate SM, Dominguez JM, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991, 51, 2720-2726.
37. Wishart GC, Plumb JA, Going JJ, et al. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990, 62, 758-761.
38. Linn SC, Giaccone G, Van Diest PJ, et al. Prognostic relevance of P-glycoprotein expression in breast cancer. Ann Oncol 1995, 6, 679-685.
39. Charpin C, Vielh P, Duffaud F, et al. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA and to immunohistochemical prognostic indicators. J Natl Cancer Inst 1994, 86, 1539-1545.
40. Haddad G, Thorner PS, Bradley G, Dalton WS, Ling V, Chan HSL. A sensitive multilayer immunoalkaline phosphatase method for detection of P-glycoprotein in leukemic and tumor cells in the bone marrow. Lab Invest 1994, 71, 595-603.
41. 4 sublines with increasing adriamycin resistance. Int J Cancer 1995, 61, 375-380.
42. Forrest MJ, Barnett D. Laboratory control of immunocytochemistry. Eur J Haematol 1989, 42, 67-71.
43. Shi T, Wrin J, Reeder J, Liu D, Ring DB. High-affinity monoclonal antibodies against P-glycoprotein. Clin Immunol Immunopathol 1995, 76, 44-51.
44. Tirikainen MI. Evaluation of red blood cell lysing solutions for the detection of intracellular antigens by flow cytometry. Cytometry 1995, 20, 341-348.
45. Cumber PM, Jacobs A, Hoy T, Whittaker JA, Tsuruo T, Padua RA. Increased drug accumulation ex vivo with cyclosporin in chronic lymphatic leukemia and its relationship to epitope mask-ing of P-glycoprotein. Leukemia 1991, 5, 1050-1053.
46. Broxterman HJ, Sonneveld P, Feller N, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood, in press.
47. Poncelet P, George F, Lavabre-Bertrand T. Application of phenotype analysis. In Masseyeff RF, Albert WH, Staines NA, eds. Methods of Immunological Analysis Vol. 3 Cells and Tissues. Weinheim, Germany, VCH Verlags, 1993, 388-417.
48. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-94.
49. + cases. Blood 1995, 86, 2329-2342.
50. Feller N, Kuiper CM, Lankelma J, et al. Functional detection of MDR1/P170 and MRP/P190 mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 1995, 72, 543-549.
51. Eijdems EWHM, Zaman GJR, De Haas M, et al. Altered MRP is associated with multidrug resistance and reduced drug accumulation in humans SW-1573 cells. Br J Cancer 1995, 72, 298-306.
52. Broxterman HJ, Versantvoort CHM. Pharmacology of drug transport in multidrug resistant tumor cells. In Kellen JA, ed. Alternative Mechanisms of Multidrug Resistance in Cancer. Boston, USA, Birkhäuser, 1995, 67-80.
53. Spoelstra EC, Dekker H, Schuurhuis GJ, Broxterman HJ, Lankelma J. P-glycoprotein drug efflux pump involved in the mechanisms of intrinsic drug resistance in various colon cancer cell lines. Evidence for saturation of active daunorubicin transport. Biochem Pharmacol 1991, 41, 349-359.
54. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992, 79, 3267-3273.
55. Mülder HS, Dekker H, Pinedo HM, Lankelma J. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. Biochem Pharmacol 1995, 50, 967-974.
56. Xie SX-Y, Robb D, Chow S, Hedley D. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia 1996, 9, 1882-1887.
57. Koizumi S, Konishi M, Ichihara T, et al. Flow cytometric functional analysis of multidrug resistance by Fluo-3; a comparison with rhodamine-123. Eur J Cancer 1995, 31A, 1682-1688.
58. Lamy T, Drenou B, Grulois I, et al. Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995, 9, 1549-1555.
59. Pilarski LM, Belch AR. Circulating monoclonal B cells expressing P-glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma. Blood 1994, 83, 724-736.
60. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Van der Hoeven JJM, Pinedo HM, Lankelma J. Daunomycin accumulation in resistant tumour cells as a screening model for resistance modifying drugs: role of protein binding. Cancer Lett 1987, 35, 87-95.
61. Mülder HS, Pinedo HM, Timmer AT, Rao BR, Lankelma J. Multidrug resistance-modifying components in human plasma with potential clinical significance. J Exp Therap Oncol 1996, 1, 13-22.
62. Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 1995, 72, 82-89.
63. Davey RA, Longhurst TJ, Davey MW, et al. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 1995, 19, 275-282.
64. Lutzky J, Astor MB, Taub RN, et al. Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res 1989, 49, 4120-4125.
65. Foot M, Kavanagh TJ, Kang HC, Haughland RP, Rabinovitch PS. Flow cytometric analysis of cell cycle-dependent changes in cell thiol level by combining a new laser dye with Hoechst 33342. Cytometry 1991, 12, 184-187.
66. Hedley DW, Chow S. Evaluation of methods for measuring cellular glutathione content using flow cytometry. Cytometry 1994, 15, 349-358.
67. Barhoumi R, Hartford Bailey R, Burghardt RC. Kinetic analysis of glutathione in anchored cells with monochlorobimane. Cytometry 1995, 19, 226-234.
68. Thomas M, Nicklee T, Hedley DW. Differential effects of depleting agents on cytoplasmic and nuclear non-protein sulphydryls: a fluorescence image cytometry study. Br J Cancer 1995, 72, 45-50.
69. Chow S, Hedley D. Flow cytometric determination of glutathione in clinical samples. Br J Cancer 1995, 21, 68-71.
70. Versantvoort CHM, Bagrij T, Wright KA. Twentyman PR. On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int J Cancer 1995, 63, 855-862.
71. Feller N, Broxterman HJ, Währer DCR, Pinedo HM. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett 1995, 368, 385-388.
72. Van der Heyden S, Gheuens E, De Bruijn E, Van Oosterom A, Maes R. P-glycoprotein: clinical significance and methods of analysis. Crit Rev Clin Lab Sci 1995, 32, 221-264.
73. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsuruo T, Pinedo HM, Lankelma J. Increase of daunorubicin and vincristine accumulation in multidrug-resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem Pharmacol 1988, 37, 2389-2393.
74. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, et al. Probing daunorubicin accumulation defects in non-P-glycoprotein expressing multidrug-resistant cell lines using digitonin. Int J Cancer 1992, 50, 906-911.
75. Chance JT, Larsen SA, Pope V, Measel JW, Cox DL. Instrument-dependent fluorochrome sensitivity in flow cytometric analyses. Cytometry 1995, 22, 232-242.
76. Schuurhuis GJ, Broxterman HJ, Cervantes A, et al. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 1989, 81, 1887-1892.
77. Schuurhuis GJ, Broxterman HJ, De Lange JHM, et al. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 1991, 64, 857-861.
78. Broxterman HJ, Versantvoort CHM, Linn SC. Multidrug resistance in lung cancer. In Hansen HH, ed. Lung Cancer. Norwell, USA, Kluwer, 1994, 193-222.
79. Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 1986, 46, 5941-5946.
80. De Vries EGE, Meijer C, Müller M, Jansen PLM, Mulder NH. Glutathione S-conjugate transport in multidrug resistant MRP-positive GLC4/ADR cell line. Proc Am Assoc Cancer Res 1995, 36, 316.
81. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993, 53, 977-984.
82. Kunikane H, Zalupski MM, Kukuruga M, et al. P-glycoprotein expression and drug efflux in soft tissue sarcoma. Proc Am Assoc Cancer Res 1995, 36, 219.
83. Broxterman HJ, Feller N, Kuiper CM, et al. Correlation between functional and molecular analysis of mdr1 P-glycoprotein in human solid-tumour xenografts. Int J Cancer 1995, 61, 880-886.
84. Broxterman HJ, Jansen G, Linn SC, Lankelma J. The impact of transport-associated resistance in anticancer chemotherapy. In Georgopapadakou NH, ed. Drug Transport in Antimicrobial and Anticancer Chemotherapy. New York, Marcel Dekker, 1995, 21-62.
85. Pinedo HM, Giaccone G. P-glycoprotein-A marker of cancer cell behavior. N Engl J Med 1995, 333, 1417-1419.
86. Germann UA, Harding MW. Chemosensitizers to overcome and prevent multidrug resistance? J Natl Cancer Inst 1995, 87, 1573-1575.